TG Therapeutics | TGTX - Equity Capital And Reserves


TG Therapeutics reported $583.13M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Amgen USD 9.19B 532M Mar/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Curis USD 5.46M 19.45M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
TG Therapeutics USD 583.13M 64.89M Mar/2026
Verastem USD 57.2M 72.72M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026